Linagliptin and metformin hydrochloride

(Jentadueto®)

Linagliptin and metformin hydrochloride

Drug updated on 9/4/2024

Dosage FormTablet (oral; linagliptin/ metformin; 2.5 mg /500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg)
Drug ClassDipeptidyl peptidase-4 inhibitors and biguanides
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Jentadueto (linagliptin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • This summary is based on the review of one randomized controlled trial(s). [1]
  • The probability of achieving normoglycemia was higher in the Linagliptin and Metformin (LM) group compared to the Metformin (M) group (OR 3.26, 95% CI: 1.55-6.84).
  • The incidence of Type 2 Diabetes (T2D) was lower in the LM group compared to the M group (HR 4.0, 95% CI: 1.24-13.04, p = 0.020).
  • The OGTT disposition index (DI), indicating pancreatic β-cell function, improved more significantly in the LM group across 6 and 24 months compared to the M group (p < 0.05).
  • No major side effects were observed during the study, and no significant safety concerns or adverse effects were highlighted in the general population of prediabetic patients with impaired glucose tolerance and additional T2D risk factors.
  • The study population consisted of prediabetic patients with impaired glucose tolerance and at least two additional T2D risk factors; in this subgroup, the Linagliptin and Metformin (LM) combination was more effective than Metformin alone in improving glucose metabolism, pancreatic β-cell function, and reducing T2D incidence.

Product Monograph / Prescribing Information

Document TitleYearSource
Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information.2023Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Randomized Controlled Trials

Clinical Practice Guidelines